Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CPX-351 + venetoclax
- Development stage
- Unknown
- Lead developer
- Jazz Pharmaceuticals
- Modality
- Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous, Oral
01
Overview
CPX-351 + venetoclax is a combination regimen consisting of CPX-351 (a dual-drug liposomal formulation containing cytarabine and daunorubicin in a fixed 5:1 molar ratio) and venetoclax (a selective small molecule inhibitor of the anti-apoptotic protein BCL-2). CPX-351 acts as an antineoplastic agent by inhibiting DNA synthesis and promoting DNA damage, while venetoclax promotes apoptosis by inhibiting BCL-2. The combination is being investigated in acute myeloid leukemia (AML), including relapsed/refractory and newly diagnosed patients unfit for intensive chemotherapy, as well as pediatric patients. Preclinical data indicate synergistic pro-apoptotic effects. Combination therapy has demonstrated promising response rates and a safety profile consistent with those of the individual agents[1][3][5][6].
- Brand names
- VyxeosVenclexta
- Other names
- daunorubicin + cytarabine liposome + venetoclax
02
Targets
TOP2A (DNA topoisomerase II)BCL-2 (BCL-2 family)DNA
Beyond the preview
Go deeper on CPX-351 + venetoclax.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CPX-351 + venetoclax.